The Ministry of Health, Labor and Welfare (MHLW) on January 10 ordered a label revision for Celgene’s multiple myeloma med Revlimid (lenalidomide) to warn of the risk of hepatitis B virus reactivation. In its notification to the Federation of Pharmaceutical…
To read the full story
Related Article
- MHLW Notifies of Package Insert Changes for Iguratimod
February 8, 2017
- PMDA Reviewing Risk of Hep B Virus Reactivation for Revlimid
December 13, 2016
REGULATORY
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Keytruda SC Heads to Japan Approval, Ipsen’s Ojemda for Conditional Nod
August 25, 2026
- Japan Grants Orphan Tags to Rogocekib, Gildeuretinol, and More
August 25, 2026
- Japan Extends Re-Examination Period for Uplizna
August 25, 2026
- 4 Drug Makers Seek Govt Aid to Upgrade Aging Plants: LDP Hearing
August 24, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





